Busulfan Intravenous and Flagyl 375

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

MetroNIDAZOLE may increase the blood levels of busulfan. This may increase the risk and/or severity of side effects such as nausea, vomiting, diarrhea, mouth sores, ulcers, hair loss, seizures, electrolyte abnormalities, liver problems, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should contact your doctor if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with metronidazole may significantly increase the plasma concentrations of busulfan. The mechanism of interaction has not been described. In a group of patients receiving myeloablative therapy with busulfan (1 mg/kg orally for 4 days) prior to undergoing hematopoietic stem cell transplantation, five patients who were coadministered metronidazole (400 mg orally three times daily for 4 days) had an 87% increase in mean busulfan trough concentrations compared to ten patients who were administered busulfan alone. In nine patients who received metronidazole only for the last 2 days of busulfan administration, busulfan concentrations increased 79% compared to the first 2 days. In patients who received busulfan and metronidazole concomitantly for 4 days, all experienced elevated liver transaminases (AST, ALT) and bilirubin. Three patients also experienced veno-occlusive disease (one died with multi-organ failure), while one developed hemorrhagic cystitis. In the group who received metronidazole only on the last two days of busulfan therapy, six had elevated liver function tests, but no veno-occlusive disease was observed.

MANAGEMENT: Due to the potential for severe toxicity and mortality associated with elevated busulfan plasma levels, concomitant use with metronidazole should be avoided. However, if concomitant therapy is necessary, close monitoring for signs of busulfan toxicity is recommended.

Busulfan Intravenous

Generic Name: busulfan

Brand name: Busulfex, Myleran

Synonyms: Busulfan (oral/injection), Busulfan

What is Busulfan Intravenous?

Flagyl 375

Generic Name: metronidazole

Brand name: FIRST Metronidazole, Flagyl, Flagyl 375, MetroGel

Synonyms: Flagyl 375 Capsules

What is Flagyl 375?